TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33942343

Group type: EXPERIMENTAL
Intervention: Single-injection of 10 mg nalbuphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: PCA-mimic method of 10 mg nalbuphine (2 mg once for five times with a 30-min interval)
Number of subjects: 20
Study: 32423734

Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography (TTE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Transesophageal Echocardiography (TEE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Modified deep transgastric view (TEE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Transgastric right ventricular inflow view (TEE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Speckle tracking TAPSE (TEE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Speckle tracking TAPSE (TTE)
Number of subjects: 25
Study: 35378301

Group type: EXPERIMENTAL
Intervention: EVO intervention (online lessons, smartphone app for self-monitoring, 12 brief calls with a Health Promotionist)
Number of subjects: 524

Group type: COMPARATOR
Intervention: DPP intervention (first 6 months of CDC's T2D materials, 16 one-hour video call sessions with certified staff)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: EVO
Number of subjects: 524

Group type: COMPARATOR
Intervention: DPP
Number of subjects: 524
Study: 34504336

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (500 ml)
Number of subjects: 940

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 940
Study: 32753300

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 36
Study: 36167537

Group type: EXPERIMENTAL
Intervention: Incremental hemodialysis (twice-weekly for 6 weeks followed by thrice-weekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional hemodialysis (thrice-weekly)
Number of subjects: 20
Study: 34038706

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34048435

Group type: EXPERIMENTAL
Intervention: Structured small-group student talk as collaborative prewriting discussions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (no structured small-group discussions)
Number of subjects: 0
Study: 34365883

Group type: EXPERIMENTAL
Intervention: Exergame-training (home-based X-box One Kinect training focused on balance for 6-8 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 35
Study: 34256795

Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation (1 pre-rehabilitation session and 9 to 12 sessions including patient education, pelvic floor muscle exercises, pelvic floor electromyography biofeedback, and capacitive and sensory rectal training with a balloon probe)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 56
Study: 35325620

Group type: EXPERIMENTAL
Intervention: HFNO alone
Number of subjects: 299

Group type: COMPARATOR
Intervention: NIV alternating with HFNO
Number of subjects: 299
Study: 33492083

Group type: EXPERIMENTAL
Intervention: Equal ratio ventilation (ERV) with I:E ratio of 1:1
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional ventilation with I:E ratio of 1:2
Number of subjects: 28
Study: 34296549

Group type: EXPERIMENTAL
Intervention: Electrical Automatic Massage (EAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32070400

Group type: EXPERIMENTAL
Intervention: Individualized high PEEP with recruitment maneuvers (RM)
Number of subjects: 1468

Group type: COMPARATOR
Intervention: Low PEEP (5 cm H2O without RM)
Number of subjects: 1468
Study: 36152744

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 22
Study: 33468271

Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry (24 g/d for 90 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: SB placebo
Number of subjects: 37
Study: 32428636

Group type: EXPERIMENTAL
Intervention: Music Therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aromatherapy & Massage
Number of subjects: 60
Study: 35709650

Group type: EXPERIMENTAL
Intervention: Metformin Glycinate (MG) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33638230

Group type: EXPERIMENTAL
Intervention: Wearing a face mask
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Handwashing/hand sanitising
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Social distancing
Number of subjects: 527
Study: 32384947

Group type: EXPERIMENTAL
Intervention: Nano-albumin paclitaxel combined with cisplatin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Traditional paclitaxel combined with cisplatin
Number of subjects: 78
Study: 34256828

Group type: EXPERIMENTAL
Intervention: Decision support intervention (DESI) for primary endocrine therapy (PET) or surgery with adjuvant therapies
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Decision support intervention (DESI) for adjuvant chemotherapy after surgery
Number of subjects: 1339

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Online risk prediction model and brief decision aid
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Decision support intervention (DESI)
Number of subjects: 1339
Study: 33156760

Group type: EXPERIMENTAL
Intervention: Biomass fuel use
Number of subjects: 1705

Group type: EXPERIMENTAL
Intervention: Exposure to toxic gases
Number of subjects: 1705

Group type: EXPERIMENTAL
Intervention: Age >40 years
Number of subjects: 1705
Study: 35894958

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 3 mg/kg body mass
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 33914729

Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 3041

Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV)
Number of subjects: 3041

Group type: COMPARATOR
Intervention: Control (Nasal placebo and IPV)
Number of subjects: 3041
Study: 36350066

Group type: EXPERIMENTAL
Intervention: Phone-delivered CBT (6, 8, or 12 weekly sessions) augmented with a CBT skills practice smartphone application
Number of subjects: 12

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) T2DM care
Number of subjects: 12
Study: 33939452

Group type: EXPERIMENTAL
Intervention: AFVP + IPS‐SE
Number of subjects: 84

Group type: COMPARATOR
Intervention: AFVP
Number of subjects: 84
Study: 32277514

Group type: EXPERIMENTAL
Intervention: Educational intervention (reading an article)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Educational intervention (watching an educational video)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Educational intervention (viewing a PowerPoint presentation)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Initial survey (before intervention)
Number of subjects: 138
Study: 34997360

Group type: EXPERIMENTAL
Intervention: SRP + thermosensitive gel containing 0.8% oligo hyaluronic acid and octenidine HCl 0.625%
Number of subjects: 34

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 34
Study: 33624945

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 270
Study: 32811715

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799
Study: 35975643

Group type: EXPERIMENTAL
Intervention: 0.247% ropivacaine in 20 mL for ACB and IPACK block
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Successful block (n = 45)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Failed block (n = 7)
Number of subjects: 52
Study: 34440942

Group type: EXPERIMENTAL
Intervention: Immersive multimodal Brain-Computer Interfacing-Virtual Reality (BCI-VR) training after bilateral neuromodulation with rTMS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Neuromodulation combined with conventional motor imagery tasks
Number of subjects: 42
Study: 33511604

Group type: EXPERIMENTAL
Intervention: Mobile stroke units (MSU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard emergency room treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ambulance and hospital treatment
Number of subjects: 0
Study: 36072939

Group type: EXPERIMENTAL
Intervention: Hyperoxemia (target PaO2 200 – 250 mmHg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normoxemia (target PaO2 80 – 120 mmHg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hyperoxemia
Number of subjects: 15
Study: 33367229

Group type: EXPERIMENTAL
Intervention: DMPA administration in the 12-14 mm group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: DMPA administration in the 15-17 mm group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: DMPA administration in the ≥ 18 mm group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: DMPA overall effect on ovulation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pre-DMPA LH concentrations
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 24-h MPA concentrations post-DMPA administration
Number of subjects: 29
Study: 32407608

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8232

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8232
Study: 35759476

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioural therapy (CBT) plus social participation program
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 172
Study: 33089545

Group type: EXPERIMENTAL
Intervention: Lifestyle weight loss interventions
Number of subjects: 242
Study: 33296470

Group type: EXPERIMENTAL
Intervention: Healthy Living Triple P (two, 2-hr group sessions delivered face-to-face or online)
Number of subjects: 17
Study: 33827851

Group type: EXPERIMENTAL
Intervention: Side-lying sleep positioning
Number of subjects: 244

Group type: COMPARATOR
Intervention: Back-lying sleep positioning
Number of subjects: 244
Study: 32386474

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) pathway
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (historically matched)
Number of subjects: 196
Study: 35186761

Group type: EXPERIMENTAL
Intervention: aBVA procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: VAB procedure
Number of subjects: 60
Study: 34886868

Group type: EXPERIMENTAL
Intervention: One-on-one, on-site clinical mentorship for 8 hours a week, every 6 weeks over 9 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-on-one, on-site clinical mentorship
Number of subjects: 0
Study: 33179268

Group type: EXPERIMENTAL
Intervention: Discharge within 28 hours after cesarean section with a home visit by a midwife the following day
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard care: Discharge after 48 hours following cesarean section
Number of subjects: 143
Study: 32567233

Group type: EXPERIMENTAL
Intervention: Oxycodone combined with flurbiprofen axetil (OF)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sufentanil combined with flurbiprofen axetil (SF)
Number of subjects: 133
Study: 36073583

Group type: EXPERIMENTAL
Intervention: Complex therapy (standard treatment + cell therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endoscopic surgical treatment
Number of subjects: 60
Study: 34294090

Group type: EXPERIMENTAL
Intervention: CNN-based segmentation software
Number of subjects: 470
Study: 35781083

Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty (RTSA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 124
Study: 34296686

Group type: EXPERIMENTAL
Intervention: Double-triggered breaths
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Severe double-triggering group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal breaths (control)
Number of subjects: 40
Study: 32906163

Group type: EXPERIMENTAL
Intervention: Complex intervention (multimodal strategy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated voice prompts at disinfectant dispensers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (pre-intervention period)
Number of subjects: 0
Study: 34274552

Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IF)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Calorie Restriction (CR)
Number of subjects: 46
Study: 32441544

Group type: EXPERIMENTAL
Intervention: Guided self-reflection intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 144
Study: 35879713

Group type: EXPERIMENTAL
Intervention: Short incision surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Minimally invasive surgery (MIS) with tool-kit
Number of subjects: 24
Study: 34476726

Group type: EXPERIMENTAL
Intervention: VLRL-RYGB
Number of subjects: 444

Group type: COMPARATOR
Intervention: S-LRYGB
Number of subjects: 444
Study: 32106328

Group type: EXPERIMENTAL
Intervention: Parenchymal RRI measurements
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hilar RRI measurements
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultrasound machine type
Number of subjects: 22

Group type: COMPARATOR
Intervention: Depth of kidney transplant
Number of subjects: 22
Study: 34910859

Group type: EXPERIMENTAL
Intervention: NVX‐CoV2373 vaccine
Number of subjects: 29949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29949
Study: 32366273

Group type: EXPERIMENTAL
Intervention: PTCM arm counseling fidelity protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTTS counseling calls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing adherence coders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counseling modules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTTS monthly calls
Number of subjects: 0

Group type: COMPARATOR
Intervention: eReferral arm counseling
Number of subjects: 0
Study: 35076930

Group type: EXPERIMENTAL
Intervention: Various strategies to handle death during clinical trials for ALS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33165918

Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg (Group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline 0.9% (Group S)
Number of subjects: 64
Study: 34383954

Group type: EXPERIMENTAL
Intervention: verinurad + allopurinol
Number of subjects: 725

Group type: COMPARATOR
Intervention: allopurinol
Number of subjects: 725

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 725
Study: 34564448

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Western-style control diet
Number of subjects: 50
Study: 35103539

Group type: EXPERIMENTAL
Intervention: Sorafenib plus 3cir‐OFF HAIC (400 mg sorafenib twice daily + 35 mg/m2 oxaliplatin followed by 600 mg/m2 5‐fluorouracil, days 1‐3)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sorafenib alone (400 mg twice daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sorafenib plus 3cir‐OFF HAIC
Number of subjects: 64
Study: 34563982

Group type: EXPERIMENTAL
Intervention: Daily low-dose aspirin (LDA) 60 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 32954768

Group type: EXPERIMENTAL
Intervention: mPADSS scale intervention group
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: mPADSS scale intervention group and Control group
Number of subjects: 118
Study: 33944909

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 144
Study: 33338437

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg every other day for 12 weeks
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo every other day for 12 weeks
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study: 33087170

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) intervention for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching and toning (ST) control intervention for 12 weeks
Number of subjects: 0
Study: 36450449

Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor (TNF) inhibitor (TNFi)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Triple therapy (sulfasalazine and hydroxychloroquine)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups (TNFi and triple therapy)
Number of subjects: 115
Study: 34403606

Group type: EXPERIMENTAL
Intervention: ≥ three lifetime sexual partners
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Primary school education
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Primigravida status
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: HIV screening and confirmatory tests
Number of subjects: 900
Study: 34314856

Group type: EXPERIMENTAL
Intervention: 12 weeks of home‐delivered medically tailored meals (MTM)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MTM + 12 months of telehealth‐delivered medical nutrition therapy (tele‐MNT)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention
Number of subjects: 600
Study: 35564908

Group type: EXPERIMENTAL
Intervention: Yoga programme for T2DM prevention (YOGA-DP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 25
Study: 33185896

Group type: EXPERIMENTAL
Intervention: Indomethacin (1.2 mg kg–1 oral dose)
Number of subjects: 25
Study: 34622548

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (3, 7 or 14 mg)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Comparator (placebo or once‐daily subcutaneous liraglutide 0.9 mg [PIONEER 9]; once‐weekly subcutaneous dulaglutide 0.75 mg [PIONEER 10])
Number of subjects: 701
Study: 32246414

Group type: EXPERIMENTAL
Intervention: OAGB after LAGB
Number of subjects: 57
Study: 36030327

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron followed by daily doses for five days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 34382412

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus ifosfamide and etoposide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ifosfamide plus etoposide
Number of subjects: 0
Study: 32703614

Group type: EXPERIMENTAL
Intervention: Pelvic floor strengthening exercises plus hip muscle strengthening exercises (PFH)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pelvic floor strengthening exercises only (PF)
Number of subjects: 47
Study: 36027576

Group type: EXPERIMENTAL
Intervention: Image-based mobile app (ICE-TI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Independent study control group
Number of subjects: 38
Study: 33652093

Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting on medication shortages
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting on missing opioid medications
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting on disposal practices
Number of subjects: 600
Study: 35588970

Group type: EXPERIMENTAL
Intervention: Rapid phenotypic antibiotic susceptibility testing (AST) with antimicrobial stewardship programmes (ASP)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional AST
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Rapid phenotypic AST
Number of subjects: 116
Study: 35689274

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo supplementation for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0
Study: 32934343

Group type: EXPERIMENTAL
Intervention: Urinary biomarker panel combining uTFF1, uADAM12, and H. pylori
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Urinary biomarker panel for stage I GC
Number of subjects: 282
Study: 34914696

Group type: EXPERIMENTAL
Intervention: 3HP facilitated directly observed therapy (DOT)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: 3HP facilitated self-administered therapy (SAT)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Informed choice between DOT and SAT using a shared decision-making aid
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: 3HP delivery strategies (aggregate outcome)
Number of subjects: 684
Study: 33395691

Group type: EXPERIMENTAL
Intervention: Regular Activity Breaks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prolonged Sitting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prolonged Standing
Number of subjects: 18
Study: 35177302

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (100 µg, two doses, intramuscular injections 28 days apart)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 33766713

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with CCTα biomarker
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with CCTα and emmprin biomarkers
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with CCTα, survivin, or BCL‐2 biomarkers
Number of subjects: 250

Group type: COMPARATOR
Intervention: No neoadjuvant chemotherapy (no-NAC)
Number of subjects: 250
Study: 33204076

Group type: EXPERIMENTAL
Intervention: XueBiJing (XBJ) injection, 100 mL, q 12 h for 5-7 days
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 35489749

Group type: EXPERIMENTAL
Intervention: S-PCI ≥ 18.5
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CT-PCI
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Residual disease (RD) of any size
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: S-PCI
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: PCI > 18.5
Number of subjects: 118
Study: 33615901

Group type: EXPERIMENTAL
Intervention: Dynamic quadriceps stretching exercises
Number of subjects: 44

Group type: COMPARATOR
Intervention: Static quadriceps stretching exercises
Number of subjects: 44